Human rhinoviruses

Samantha E. Jacobs, Daryl M. Lamson, St Kirsten, Thomas J. Walsh

Research output: Contribution to journalArticle

Abstract

Human rhinoviruses (HRVs), first discovered in the 1950s, are responsible for more than one-half of cold-like illnesses and cost billions of dollars annually in medical visits and missed days of work. Advances in molecular methods have enhanced our understanding of the genomic structure of HRV and have led to the characterization of three genetically distinct HRV groups, designated groups A, B, and C, within the genus Enterovirus and the family Picornaviridae. HRVs are traditionally associated with upper respiratory tract infection, otitis media, and sinusitis. In recent years, the increasing implementation of PCR assays for respiratory virus detection in clinical laboratories has facilitated the recognition of HRV as a lower respiratory tract pathogen, particularly in patients with asthma, infants, elderly patients, and immunocompromised hosts. Cultured isolates of HRV remain important for studies of viral characteristics and disease pathogenesis. Indeed, whether the clinical manifestations of HRV are related directly to viral pathogenicity or secondary to the host immune response is the subject of ongoing research. There are currently no approved antiviral therapies for HRVs, and treatment remains primarily supportive. This review provides a comprehensive, up-to-date assessment of the basic virology, pathogenesis, clinical epidemiology, and laboratory features of and treatment and prevention strategies for HRVs.

Original languageEnglish (US)
Pages (from-to)135-162
Number of pages28
JournalClinical Microbiology Reviews
Volume26
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Rhinovirus
Picornaviridae
Virology
Cost of Illness
Enterovirus
Sinusitis
Otitis Media
Immunocompromised Host
Virus Diseases
Respiratory Tract Infections
Respiratory System
Antiviral Agents
Virulence
Epidemiology
Therapeutics
Asthma
Viruses
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Epidemiology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Jacobs, S. E., Lamson, D. M., Kirsten, S., & Walsh, T. J. (2013). Human rhinoviruses. Clinical Microbiology Reviews, 26(1), 135-162. https://doi.org/10.1128/CMR.00077-12

Human rhinoviruses. / Jacobs, Samantha E.; Lamson, Daryl M.; Kirsten, St; Walsh, Thomas J.

In: Clinical Microbiology Reviews, Vol. 26, No. 1, 01.2013, p. 135-162.

Research output: Contribution to journalArticle

Jacobs, SE, Lamson, DM, Kirsten, S & Walsh, TJ 2013, 'Human rhinoviruses', Clinical Microbiology Reviews, vol. 26, no. 1, pp. 135-162. https://doi.org/10.1128/CMR.00077-12
Jacobs SE, Lamson DM, Kirsten S, Walsh TJ. Human rhinoviruses. Clinical Microbiology Reviews. 2013 Jan;26(1):135-162. https://doi.org/10.1128/CMR.00077-12
Jacobs, Samantha E. ; Lamson, Daryl M. ; Kirsten, St ; Walsh, Thomas J. / Human rhinoviruses. In: Clinical Microbiology Reviews. 2013 ; Vol. 26, No. 1. pp. 135-162.
@article{6760c370aad0423ba416ba971128810d,
title = "Human rhinoviruses",
abstract = "Human rhinoviruses (HRVs), first discovered in the 1950s, are responsible for more than one-half of cold-like illnesses and cost billions of dollars annually in medical visits and missed days of work. Advances in molecular methods have enhanced our understanding of the genomic structure of HRV and have led to the characterization of three genetically distinct HRV groups, designated groups A, B, and C, within the genus Enterovirus and the family Picornaviridae. HRVs are traditionally associated with upper respiratory tract infection, otitis media, and sinusitis. In recent years, the increasing implementation of PCR assays for respiratory virus detection in clinical laboratories has facilitated the recognition of HRV as a lower respiratory tract pathogen, particularly in patients with asthma, infants, elderly patients, and immunocompromised hosts. Cultured isolates of HRV remain important for studies of viral characteristics and disease pathogenesis. Indeed, whether the clinical manifestations of HRV are related directly to viral pathogenicity or secondary to the host immune response is the subject of ongoing research. There are currently no approved antiviral therapies for HRVs, and treatment remains primarily supportive. This review provides a comprehensive, up-to-date assessment of the basic virology, pathogenesis, clinical epidemiology, and laboratory features of and treatment and prevention strategies for HRVs.",
author = "Jacobs, {Samantha E.} and Lamson, {Daryl M.} and St Kirsten and Walsh, {Thomas J.}",
year = "2013",
month = "1",
doi = "10.1128/CMR.00077-12",
language = "English (US)",
volume = "26",
pages = "135--162",
journal = "Clinical Microbiology Reviews",
issn = "0893-8512",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Human rhinoviruses

AU - Jacobs, Samantha E.

AU - Lamson, Daryl M.

AU - Kirsten, St

AU - Walsh, Thomas J.

PY - 2013/1

Y1 - 2013/1

N2 - Human rhinoviruses (HRVs), first discovered in the 1950s, are responsible for more than one-half of cold-like illnesses and cost billions of dollars annually in medical visits and missed days of work. Advances in molecular methods have enhanced our understanding of the genomic structure of HRV and have led to the characterization of three genetically distinct HRV groups, designated groups A, B, and C, within the genus Enterovirus and the family Picornaviridae. HRVs are traditionally associated with upper respiratory tract infection, otitis media, and sinusitis. In recent years, the increasing implementation of PCR assays for respiratory virus detection in clinical laboratories has facilitated the recognition of HRV as a lower respiratory tract pathogen, particularly in patients with asthma, infants, elderly patients, and immunocompromised hosts. Cultured isolates of HRV remain important for studies of viral characteristics and disease pathogenesis. Indeed, whether the clinical manifestations of HRV are related directly to viral pathogenicity or secondary to the host immune response is the subject of ongoing research. There are currently no approved antiviral therapies for HRVs, and treatment remains primarily supportive. This review provides a comprehensive, up-to-date assessment of the basic virology, pathogenesis, clinical epidemiology, and laboratory features of and treatment and prevention strategies for HRVs.

AB - Human rhinoviruses (HRVs), first discovered in the 1950s, are responsible for more than one-half of cold-like illnesses and cost billions of dollars annually in medical visits and missed days of work. Advances in molecular methods have enhanced our understanding of the genomic structure of HRV and have led to the characterization of three genetically distinct HRV groups, designated groups A, B, and C, within the genus Enterovirus and the family Picornaviridae. HRVs are traditionally associated with upper respiratory tract infection, otitis media, and sinusitis. In recent years, the increasing implementation of PCR assays for respiratory virus detection in clinical laboratories has facilitated the recognition of HRV as a lower respiratory tract pathogen, particularly in patients with asthma, infants, elderly patients, and immunocompromised hosts. Cultured isolates of HRV remain important for studies of viral characteristics and disease pathogenesis. Indeed, whether the clinical manifestations of HRV are related directly to viral pathogenicity or secondary to the host immune response is the subject of ongoing research. There are currently no approved antiviral therapies for HRVs, and treatment remains primarily supportive. This review provides a comprehensive, up-to-date assessment of the basic virology, pathogenesis, clinical epidemiology, and laboratory features of and treatment and prevention strategies for HRVs.

UR - http://www.scopus.com/inward/record.url?scp=84872196374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872196374&partnerID=8YFLogxK

U2 - 10.1128/CMR.00077-12

DO - 10.1128/CMR.00077-12

M3 - Article

VL - 26

SP - 135

EP - 162

JO - Clinical Microbiology Reviews

JF - Clinical Microbiology Reviews

SN - 0893-8512

IS - 1

ER -